Immunex' highly purified interleukin-2 receptor
Executive Summary
Biotech firm announced it received a patent for its highly purified interleukin-2 receptor. Immunex maintained the patent is the first to cover a process for producing the receptor in a highly purified state, free of other proteins. The company said it is developing the receptor as a potential treatment for autoimmune diseases, including rheumatoid arthritis.